

**COMPARISON BETWEEN THE RESULTS  
OF LIVER TRANSPLANTATION FROM  
LIVING DONORS COMPARED TO  
CADAVERIC DONORS**

**Essay**

Submitted for Partial Fulfillment of Master Degree in  
**General Surgery**

Presented By  
**Ahmed Mohiy El-Din Ahmed Rashwan**  
M.B., B.CH.

Under Supervision of  
**PROFESSOR DR./ AWAD HASSAN AL KAYAL**

Professor of General Surgery  
Faculty of Medicine, Ain Shams University

**DOCTOR / MOHAMED AHMED MAHMOUD AAMER**

Assistant Professor of General Surgery  
Faculty of Medicine, Ain Shams University

Faculty of Medicine  
Ain Shams University  
2013

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

﴿قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا

عَلَّمْتَنَا إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ (32)﴾

صدق الله العظيم

البقرة آية "32"



## *Dedication*

*For God whose blessing gave me  
The strength to accomplish this  
work, my parents, wife, daughter  
and my son whose love and  
Encouragement helped me to be the  
person I am*

*Ahmed Mohiy El-Din Ahmed Rashwan*

## *Acknowledgement*

*I would like to express my deepest gratitude and sincere thanks to Prof. Dr. Awad Hassan Al Kayal, Professor of Surgery, Faculty of Medicine, Ain Shams University, for kindly accepting to supervise this work and for the valuable advice and encouragement he honestly offered throughout the course of this work.*

*Also, I would like to express my limitless gratitude and special grateful thanks and appreciation to Dr. Mohamed Ahmed Mahmoud Aamer, Assistant Professor of Surgery , Faculty of Medicine, Ain Shams University, for sincere continuous help, true advice, valuable guidance, kind supervision and constant purposeful encouragement which provided me all facilities during the conduction of this work.*

*Ahmed Mohiy El-Din Ahmed Rashwan*

## **List of Abbreviations**

<b>ACR</b>	:	Acute Cellular Rejection.
<b>AFHF</b>	:	Acute Fulminant Hepatic Failure.
<b>ALT</b>	:	Alanine aminotransferase.
<b>ARDS</b>	:	Adult Respiratory Distress Syndrome.
<b>ARE</b>	:	Acute Rejection Episode.
<b>AST</b>	:	Aspartate aminotransferase.
<b>AZA</b>	:	Azathioprine.
<b>BMI</b>	:	Body Mass Index.
<b>CD-CD</b>	:	Choledocho-Choledochostomy.
<b>CD-j</b>	:	Choledocho-Jejunostomy.
<b>CHD</b>	:	Common Hepatic Duct.
<b>CLD</b>	:	Chronic Liver Disease.
<b>CLT</b>	:	Cadaveric Liver Transplantation.
<b>CMV</b>	:	Cytomegalovirus.
<b>CNHBD</b>	:	Controlled Non Heart Beating Donors.
<b>CR</b>	:	Chronic Rejection.
<b>CsA</b>	:	Cyclosporine A.
<b>CT</b>	:	Computed Tomography.
<b>CTP</b>	:	Child- Turcotte- Pugh.

<b>CUSA</b>	:	Cavitron Ultrasonic Surgical Aspirator.
<b>CV</b>	:	Coronary Vein.
<b>CWLT</b>	:	Cadaveric Whole Liver Transplantation.
<b>EAD</b>	:	Early Allograft Dysfunction.
<b>EBV</b>	:	Epstein-Barr virus.
<b>ELTA</b>	:	Egyptian Liver Transplantation Association.
<b>ERCP</b>	:	Endoscopic Retrograde Cholangiopancreatography
<b>ESLD</b>	:	End Stage Liver Disease.
<b>FAP</b>	:	Familial Amyloidotic Polyneuropathy.
<b>FFP</b>	:	Fresh Frozen Plasma.
<b>GGT</b>	:	Gamma-Glutamyl Transferase.
<b>GRWR</b>	:	Graft Volume Recipient Body Weight Ratio.
<b>GSV</b>	:	Great Saphenous Vein.
<b>HAT</b>	:	Hepatic Artery Thrombosis.
<b>HBDD</b>	:	Heart-Beating, Brain-Dead cadaveric Donors.
<b>HBIG</b>	:	Hepatitis B Immunoglobulin.
<b>HBV</b>	:	Hepatitis B Virus.
<b>HCC</b>	:	Hepatocellular Carcinoma.
<b>HCV</b>	:	Hepatitis C Virus.
<b>HHD</b>	:	High Hilar Dissection.
<b>HIV</b>	:	Human Immunodeficiency Virus.
<b>HRS</b>	:	Hepatic Renal Syndrome.

<b>HSV</b>	:	Herpes Simplex Virus.
<b>HTK</b>	:	Histidine-Tryptophan-Ketoglutarate solution.
<b>ICU</b>	:	Intensive Care Unit.
<b>IFN-<math>\alpha</math></b>	:	Interferon alpha.
<b>IMV</b>	:	Inferior Mesenteric Vein.
<b>IVC</b>	:	Inferior Vena Cava.
<b>LDLT</b>	:	Living Donor Liver Transplantation.
<b>LHV</b>	:	Left Hepatic Vein.
<b>LPV</b>	:	Left Portal Vein.
<b>LRLT</b>	:	Living Related Liver Transplantation.
<b>LT</b>	:	Liver Transplantation.
<b>MELD</b>	:	Model for End-Stage Liver Disease.
<b>MHV</b>	:	Middle Hepatic Vein.
<b>MMF</b>	:	Mycophenolate Mofetil.
<b>MRI</b>	:	Magnetic Resonance Imaging.
<b>NIH</b>	:	National Institutes of Health.
<b>NSAIDs</b>	:	Non-Steroidal Anti-Inflammatory Drugs.
<b>PBC</b>	:	Primary Biliary Cirrhosis.
<b>PNF</b>	:	Primary Non-Function.
<b>PNFG</b>	:	Primary Non-functioning Graft.
<b>PS</b>	:	Prolene Suture.
<b>PSC</b>	:	Primary Schlerosing Cholangitis.

<b>PVT</b>	:	Portal Vein Thrombosis.
<b>RHV</b>	:	Right Hepatic Vein.
<b>RL</b>	:	Right Lobe.
<b>RLT</b>	:	Reduced Liver Transplantation.
<b>RPV</b>	:	Right Portal Vein.
<b>RYHJ</b>	:	Roux-en-Y Hepaticojejunostomy.
<b>SLV</b>	:	Standard Liver Volume.
<b>SMA</b>	:	Superior Mesenteric Artery.
<b>SMV</b>	:	Superior Mesenteric Vein.
<b>SV</b>	:	Splenic Vein.
<b>TAC</b>	:	Tacrolimus.
<b>TIPS</b>	:	Trans-jugular Intrahepatic Porto systemic Shunt.
<b>UNOS</b>	:	United Network of Organ Sharing.
<b>UW</b>	:	University of Wisconsin.



## **List of Figures**

<b>Title</b>	<b>Page No.</b>
Fig.(1):The Visceral Surface Of The Liver.	18
Fig.(2):Peritoneal Attachment Of The Liver.	20
Fig.(3):The Fissure And Sectors Of The liver.	25
Fig.(4):Diagrammatic Representation Of The 8 Segments Of The Liver.	27
Fig.(5):Exploded Segmental View Of The Liver Emphasizing The Intrahepatic Anatomy And hepatic Veins.	28
Fig.(6):Anatomy Of Extrahepatic And Intrahepatic Portal Vein.	34
Fig.(7):Hepatic Arterial Anatomy.	39
Fig.(8):The Major Hepatic Veins.	42
Fig.(9):The Tributaries Of The Hepatic Veins In Relation to The Liver Segments (II-VIII). LHV: Left Hepatic Vein, MHV: Middle Hepatic Vein, RHV: Right Hepatic Vein.	42

## **List of Tables**

<b>Title</b>	<b>Page No.</b>
Table (1): Disease Indications for Liver Transplantation.	48
Table (2): Contraindications Of Liver Transplantation.	53
Table (3): Classifications Of Common Complications Of Liver Transplantation .	74

## **Contents**

<b>Title</b>	<b>Page No.</b>
1- Introduction And Aim Of The Work.	1 – 6
2- History Of Liver Transplantation.	7 – 14
3- Surgical Anatomy Of Liver.	15 – 47
4- Indications Of Liver Transplantation.	48 – 52
5- Contraindications Of Liver Transplantation.	53 – 56
6- Living Donor Liver Transplantation.	57 – 59
7- Cadaveric Liver Transplantation.	60 – 65
8- Post-transplant Management.	66 – 73
9- Complications Of Liver Transplantation.	74 – 103
10- Results Of Liver Transplantation.	104 – 108
11- Summary And Conclusions.	109 – 111
12- References.	112 – 135
13- Arabic Summary.	-

**Introduction**

**And**

**Aim Of The Work**



## **Introduction**

In 1963, Starzl performed the first human orthotopic liver transplantation, and in 1967 the first successful liver transplantation was done. Since then, liver transplantation started to be thought of as a line of treatment for patients with end-stage liver disease. **(Starzl et al., 1982).**

The main source of donor organs is the brainstem-dead, heart-beating donor. There are few absolute contraindications to organ donation but, with the increasing waiting list mortality and waiting times, donor acceptance criteria have been liberalised and numerous technical variant grafts (reduced liver, split liver, living donor liver, domino liver) have been adopted to reduce this shortfall **(Mehta and Mirza, 2007).**

The goal of liver transplantation is to prolong and improve quality of life in patients with advanced liver diseases (acute or chronic end-stage liver diseases). Selection and timing of referral for evaluation for liver transplantation optimizes outcomes. Patients are listed for transplantation after a complete assessment by a multidisciplinary team. The incidence of postoperative complications is influenced by the quality of the donor liver, technical aspects of the surgery, and recipient factors. Patient survival at one year and five years is 85–90% and

75–80%, respectively; graft survival is 80–85% and 70–75%, respectively. The main factor limiting further growth in liver transplantation worldwide is shortage of donor organs **(Mehta and Mirza, 2007)**.

Age , sex , underlying liver disease , hepatitis viral infection (B and C viruses) , immunosuppressive regimen , ABO blood groups and HLA class I and II mismatches have a major impact on the outcome of liver transplantation. **(Hoffman et al, 1995)**.

Hepatitis C is among the most common causes of chronic liver disease affecting approximately 1% of the world's population . End-stage hepatitis C Virus (HCV) related chronic liver disease is the leading indication for orthotropic liver transplantation worldwide . **(Strader and Seef , 1996) .**

Hepatitis C virus (HCV) is a leading cause of liver cancer and Egypt has possibly the highest HCV prevalence **(Pybus et al., 2003)**.

Patients with chronic hepatitis C do much better following liver transplantation than do patients with chronic hepatitis B . **(Martin et al.,1992) .**

Cadaveric liver transplantation (CLT) (5-year survival >80%) represents the standard of care for end-stage liver disease (ESLD). Because the demand for cadaveric organs exceeds their